About the Company
oric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ORIC News
These Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 Results
ORIC Pharmaceuticals shares fell 2.4% to trade at $14.63 on Tuesday. These analysts made changes to their price targets on ...
ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
ORIC Pharmaceuticals has reported positive preliminary results for three programs in its pipeline. Check out why I rate ORIC ...
ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results
Warning! GuruFocus has detected 3 Warning Sign with ORIC. On March 11, 2024, ORIC Pharmaceuticals Inc (NASDAQ:ORIC) released its 8-K filing, detailing the fourth quarter and full year financial ...
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 ...
ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares
Jacob Chacko, the President and Chief Executive Officer of ORIC Pharmaceuticals Inc (NASDAQ:ORIC), has sold 40,000 shares of the company on March 6, 2024, according to a recent SEC Filing.
ORIC Pharmaceuticals GAAP EPS of -$0.49
Q4 GAAP EPS of -$0.49. Research and development expenses were $24.5M for the three months ended December 31, 2023, compared to $16.3M for the three months ended December 31, 2022, an increase of $8.2M ...
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed ...
Outlook Therapeutics stock undergoes 1-for-20 reverse stock split
The reverse stock split is “part of the Company’s plan to regain compliance with the minimum bid price requirement for ...
Regenxbio raised to Buy at RBC on pivot to Duchenne
Regenxbio (RGNX) stock rises as RBC Capital Markets upgrades the gene therapy developer, citing its potential against Duchenne muscular dystrophy. Read more here.
Loading the latest forecasts...